openpr.com
Cure8 news brief
Mobius Care Receives Funding from Crohn's & Colitis Foundation
Research and clinical trials
Biomarkers
AI and data science
Biomarker
Clinical study
Patients On Biologics
Clinicians
Researchers
Why This Matters
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or ulcerative colitis.
Foundation funding signals institutional interest and support for precision diagnostics in IBD.
Who Should Pay Attention
People with IBD (including those trying biologics or other advanced therapies), clinicians who treat IBD, and researchers working on biomarkers, digital pathology, or AI in gastroenterology.
Study Snapshot
Story typePress release
Evidence typeClinical study
Source depthFull source text
What To Know
Mobius Care announced funding from the Crohn's & Colitis Foundation to advance an H&E image–based predictive biomarker that uses AI to predict response to existing IBD therapies.
The technology is described as a digital pathology test built on AI analysis of standard H&E slides and aims to support precision selection of treatments and development of therapeutics. This appears to be an early-stage diagnostic/biomarker development and funding announcement rather than publication of new clinical trial results.
The release references prior 2021 research by the team showing epithelial cell biomarkers could predict response, and frames the current funding as support to advance the AI-powered biomarker and an expanding therapeutic pipeline.
The piece is a press release about a funding partnership; it does not provide outcome data, performance metrics, or regulatory status for the biomarker.
Keep In Mind
This is a funding/press announcement about development of an AI-based H&E biomarker. It does not report new clinical validation results or regulatory approvals. Patients should not change treatments based on this release; follow-up publications or regulatory updates will be needed to judge clinical utility.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationopenpr.com
Indexed viaGoogle News
Source typePress release
PublishedFeb 14, 2025, 8:02 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Is There a Blood Test That Distinguishes Crohn's Disease From UC? - HealthCentral
Distinguishing Crohn’s from ulcerative colitis can be hard and often requires invasive tests. A reliable blood test would speed diagnosis and help patients start the right treatments sooner. This study is an early step...
Machine Learning Model Identifies Gut Biomarkers That May Help Diagnose IBD Patients
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
Impact of Amerindian ancestry on clinical outcomes in Crohn's disease and ulcerative colitis ...
Genetic ancestry can influence IBD risk and disease course, and most prior studies focused on European populations.